We improve the lives of patients through the design of precise cancer therapeutics. Until now, RSK has been undruggable. Our work focuses on developing novel drugs targeting RSK, a driver in cancerous tumor growth and metastases.
RSK signalling controls the growth of at least 14 different types of cancer ranging from solid tumors to hematological malignancies. Our initial focus is on treating breast cancer, where RSK2 is shown to be a driver in disease development. This pathway is associated with resistance to endocrine therapies, as well as, targeted agents such as CDK4/6 inhibitors.
We are leaders in the field of RSK inhibition and are launching the first-in-human Phase 2 clinical trial with our lead candidate, PMD-026, in breast cancer patients.
Our patented cancer compounds position us in the lead to streamline our product to market through patient selection using a companion diagnostic to identify cancer patients who will optimally benefit from RSK-targeted therapies.